Julio Martinez-Clark’s Bioaccess combines regional partnerships across Latin America, Eastern Europe, and Australia with regulatory expertise to secure predictable approvals in weeks rather than years, enabling biotech startups to accelerate human trials and bring innovative longevity and medical therapies to market more cost-effectively.
Key points
- Global network across Latin America, Eastern Europe, and Australia reduces regulatory approval to under 30 days.
- Bioaccess standardizes submission packages, liaises with health authorities, and manages site activation to shave 3–5 years off trials.
- Facilitates advanced modalities—including BCIs, gene therapies, and theranostic radiopharmaceuticals—delivering longevity innovations efficiently.
Why it matters: By slashing approval timelines and costs, Bioaccess’s approach reshapes drug development, delivering cutting-edge longevity therapies to patients sooner and enhancing global healthcare innovation.
Q&A
- What is first-in-human (FIH) trial acceleration?
- Why are Latin America and Eastern Europe preferred?
- How does Bioaccess navigate varied regulations?
- What role do theranostics play?